KR20170064550A - 인간화 항-ox40 항체 및 이의 용도 - Google Patents

인간화 항-ox40 항체 및 이의 용도 Download PDF

Info

Publication number
KR20170064550A
KR20170064550A KR1020177012413A KR20177012413A KR20170064550A KR 20170064550 A KR20170064550 A KR 20170064550A KR 1020177012413 A KR1020177012413 A KR 1020177012413A KR 20177012413 A KR20177012413 A KR 20177012413A KR 20170064550 A KR20170064550 A KR 20170064550A
Authority
KR
South Korea
Prior art keywords
cells
antibody
seq
fragment
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020177012413A
Other languages
English (en)
Korean (ko)
Inventor
스캇 에이 해먼드
마이클 오베스트
퀀 두
멜리싸 담슈로더
Original Assignee
메디뮨 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메디뮨 엘엘씨 filed Critical 메디뮨 엘엘씨
Publication of KR20170064550A publication Critical patent/KR20170064550A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020177012413A 2014-10-10 2015-10-07 인간화 항-ox40 항체 및 이의 용도 Withdrawn KR20170064550A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462062431P 2014-10-10 2014-10-10
US62/062,431 2014-10-10
PCT/US2015/054490 WO2016057667A1 (en) 2014-10-10 2015-10-07 Humanized anti-ox40 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
KR20170064550A true KR20170064550A (ko) 2017-06-09

Family

ID=55130798

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177012413A Withdrawn KR20170064550A (ko) 2014-10-10 2015-10-07 인간화 항-ox40 항체 및 이의 용도

Country Status (19)

Country Link
US (3) US9738723B2 (enExample)
EP (1) EP3204422B1 (enExample)
JP (2) JP6794348B2 (enExample)
KR (1) KR20170064550A (enExample)
CN (1) CN107074953A (enExample)
AR (1) AR102239A1 (enExample)
AU (1) AU2015328090A1 (enExample)
BR (1) BR112017007170A2 (enExample)
CA (1) CA2963798A1 (enExample)
CL (1) CL2017000885A1 (enExample)
CO (1) CO2017004516A2 (enExample)
ES (1) ES2914177T3 (enExample)
GB (1) GB2536324A (enExample)
IL (1) IL251537A0 (enExample)
MX (1) MX2017004715A (enExample)
RU (1) RU2709742C2 (enExample)
SG (1) SG11201702826XA (enExample)
TW (1) TW201619200A (enExample)
WO (1) WO2016057667A1 (enExample)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ712903A (en) 2013-03-18 2018-07-27 Biocerox Prod Bv Humanized anti-cd134 (ox40) antibodies and uses thereof
CA2934028A1 (en) * 2013-12-17 2015-06-25 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
RU2016142476A (ru) 2014-03-31 2018-05-07 Дженентек, Инк. Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
RS63384B1 (sr) * 2015-01-08 2022-08-31 BioNTech SE Agonistička sredstva za vezivanje tnf receptora
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
PH12017502013B1 (en) 2015-05-07 2022-07-22 Agenus Inc Anti-ox40 antibodies and methods of use thereof
US20160347848A1 (en) * 2015-05-28 2016-12-01 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
UY36687A (es) 2015-05-29 2016-11-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Anticuerpos contra ox40 y sus usos
MA43017A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Anticorps bispécifiques spécifiques d'un récepteur de co-stimulation du tnf
CN108137684B (zh) 2015-10-15 2022-03-08 苏州丁孚靶点生物技术有限公司 抗ox40抗体及其应用
SG10201912984WA (en) 2015-12-02 2020-03-30 Agenus Inc Antibodies and methods of use thereof
IL321475A (en) 2016-05-06 2025-08-01 Medimmune Llc Bispecific binding proteins and their uses
TWI640536B (zh) 2016-06-20 2018-11-11 克馬伯有限公司 抗體
TW201831513A (zh) 2016-06-20 2018-09-01 Ｆ星貝塔有限公司 結合物件(一)
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
US20190330374A1 (en) * 2016-07-20 2019-10-31 Igm Biosciences, Inc. Multimeric ox40 binding molecules and uses thereof
EP3494139B1 (en) 2016-08-05 2022-01-12 F. Hoffmann-La Roche AG Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
EP3538152A4 (en) 2016-11-09 2020-09-30 Agenus Inc. ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES, AND PROCESSES FOR USE
PE20191403A1 (es) 2016-12-15 2019-10-04 Abbvie Biotherapeutics Inc Anticuerpos anti-ox40 y sus usos
WO2018115003A2 (en) 2016-12-19 2018-06-28 Glenmark Pharmaceuticals S.A. Novel tnfr agonists and uses thereof
WO2018178055A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
WO2018193102A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
WO2018193104A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-cd25 antibody-drug conjugate
JP2021501801A (ja) * 2017-11-01 2021-01-21 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 癌の処置に用いるための免疫刺激アゴニスト抗体
WO2019100320A1 (en) * 2017-11-24 2019-05-31 Eucure (Beijing) Biopharma Co., Ltd Anti-ox40 antibodies and uses thereof
AU2018394939B2 (en) 2017-12-29 2022-02-24 Ap Biosciences, Inc. Monospecific and bispecific proteins with immune checkpoint regulation for cancer therapy
CN108218990B (zh) * 2017-12-29 2021-03-02 南京优迈生物科技有限公司 分离的抗体或其抗原结合片段及其在肿瘤治疗中的应用
CN110092832B (zh) * 2018-01-29 2020-03-31 康源博创生物科技(北京)有限公司 抗ox40抗体及其用途
WO2019178852A1 (zh) * 2018-03-23 2019-09-26 苏州丁孚靶点生物技术有限公司 Ox40抗原多肽及其用途
BR112020018539A2 (pt) 2018-03-23 2020-12-29 Bristol-Myers Squibb Company Anticorpos contra mica e/ou micb e usos dos mesmos
KR102825164B1 (ko) 2018-03-27 2025-06-26 브리스톨-마이어스 스큅 컴퍼니 자외선 신호를 사용한 단백질 농도의 실시간 모니터링
CN114685665B (zh) 2018-05-11 2025-02-14 无锡药明生物技术股份有限公司 抗ox40的全人抗体及其制备方法和用途
JP2021524449A (ja) 2018-05-23 2021-09-13 アーデーセー セラピューティクス ソシエテ アノニム 分子アジュバント
BR112020023746A2 (pt) * 2018-05-23 2021-02-17 Beigene, Ltd. anticorpo, composição farmacêutica, método para tratar câncer, ácido nucleico isolado, vetor, célula hospedeira, processo para a produção de um anticorpo e reagente de diagnóstico
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
US12344672B2 (en) 2018-07-12 2025-07-01 Invox Pharma Limited Antibody molecules that bind PD-L1 and CD137
MX2021000399A (es) 2018-07-12 2021-05-27 F Star Therapeutics Ltd Moleculas de anticuerpo que se unen a cd137 y ox40.
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
US20210277135A1 (en) 2018-07-13 2021-09-09 Bristol-Myers Squibb Company Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a method of treating a cancer or a solid tumor
CN111040034B (zh) * 2018-10-12 2022-08-30 广东旋玉健康生物科技有限公司 一种抗人cd358的单克隆抗体及其用途
TW202028222A (zh) 2018-11-14 2020-08-01 美商Ionis製藥公司 Foxp3表現之調節劑
WO2020108463A1 (zh) * 2018-11-26 2020-06-04 南京金斯瑞生物科技有限公司 人源化抗人ox40单克隆抗体及其制备方法和用途
WO2020119789A1 (en) * 2018-12-14 2020-06-18 Wuxi Biologics (Shanghai) Co., Ltd. Fully human antibodies against ox40, method for preparing the same, and use thereof
US12195545B2 (en) 2018-12-25 2025-01-14 Hanx Biopharmaceutics, Inc Anti-OX40 monoclonal antibody and application thereof
US10442866B1 (en) * 2019-01-23 2019-10-15 Beijing Mabworks Biotech Co. Ltd Antibodies binding OX40 and uses thereof
WO2020172658A1 (en) 2019-02-24 2020-08-27 Bristol-Myers Squibb Company Methods of isolating a protein
MX2021010152A (es) 2019-02-27 2021-09-14 Ionis Pharmaceuticals Inc Moduladores de la expresion de malat1.
US20220152085A1 (en) * 2019-03-25 2022-05-19 Ohio State Innovation Foundation Combination immunoregulation and uses thereof
US20220220430A1 (en) 2019-05-23 2022-07-14 Bristol-Myers Squibb Company Methods of monitoring cell culture media
WO2020243568A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
WO2020243563A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Multi-tumor gene signatures for suitability to immuno-oncology therapy
CN114174537A (zh) 2019-05-30 2022-03-11 百时美施贵宝公司 细胞定位特征和组合疗法
WO2021098758A1 (en) * 2019-11-21 2021-05-27 Beigene, Ltd. Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tim3 antibodies
CN114746446A (zh) * 2019-11-21 2022-07-12 百济神州有限公司 使用抗ox40抗体与抗tigit抗体组合治疗癌症的方法
EP4061851A4 (en) * 2019-11-21 2023-12-20 BeiGene, Ltd. METHODS OF TREATING CANCER USING ANTI-OX40 ANTIBODIES IN COMBINATION WITH PI3 KINASE DELTA INHIBITORS
CA3156931A1 (en) * 2019-11-21 2021-05-27 Beibei JIANG Methods of cancer treatment using anti-ox40 antibodies in combination with anti-pd1 or anti-pdl1 antibodies
WO2021098748A1 (en) * 2019-11-21 2021-05-27 Beigene (Beijing) Co., Ltd. Methods of cancer treatment with anti-ox40 antibody in combination with chemotherapeutic agents
GB201917254D0 (en) 2019-11-27 2020-01-08 Adc Therapeutics Sa Combination therapy
WO2021111636A1 (ja) * 2019-12-06 2021-06-10 大塚製薬株式会社 抗ｇｄｆ１５抗体
CN114867749A (zh) 2019-12-17 2022-08-05 安进公司 用于疗法中的双重白介素-2/tnf受体激动剂
EP4130039A4 (en) 2020-03-23 2024-07-31 Bio-Thera Solutions, Ltd. DEVELOPMENT AND APPLICATION OF AN IMMUNE CELL ACTIVATOR
AU2021256226A1 (en) * 2020-04-17 2022-11-17 Hutchison Medipharma Limited Anti-OX40 antibody and uses thereof
EP4149974A1 (en) 2020-05-13 2023-03-22 Institut National de la Santé et de la Recherche Médicale (INSERM) Recombinant proteins with ox40 activating properties
IL300916A (en) 2020-08-31 2023-04-01 Bristol Myers Squibb Co Cell localization signature and immunotherapy
US20230374064A1 (en) 2020-10-05 2023-11-23 Bristol-Myers Squibb Company Methods for concentrating proteins
CN114457022A (zh) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 一种表达ox40激活型抗体的多能干细胞及其衍生物与应用
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
CN116635064A (zh) 2020-12-18 2023-08-22 世纪治疗股份有限公司 具有适应性受体特异性的嵌合抗原受体系统
MX2023007650A (es) 2020-12-28 2023-09-11 Bristol Myers Squibb Co Metodos de tratamiento de tumores.
WO2022146947A1 (en) 2020-12-28 2022-07-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型ｃｄｃｐ１に対する抗体およびその使用
CA3223942A1 (en) * 2021-06-29 2023-01-05 Hifibio (Hk) Limited Anti-ox40 monoclonal antibody and methods of use thereof
EP4448579A4 (en) 2021-12-17 2026-02-18 Shanghai Henlius Biotech Inc ANTI-OX40 ANTIBODIES AND METHODS OF USE
CA3240585A1 (en) 2021-12-17 2023-06-22 Wenfeng Xu Anti-ox40 antibodies, multispecific antibodies and methods of use
EP4475879A1 (en) 2022-02-08 2024-12-18 Hookipa Biotech GmbH Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines
JP2025509274A (ja) 2022-03-09 2025-04-11 ブリストル－マイヤーズ スクイブ カンパニー 治療用タンパク質の一過性発現
JP2025509749A (ja) 2022-03-18 2025-04-11 ブリストル－マイヤーズ スクイブ カンパニー ポリペプチドの単離方法
CN114591988B (zh) * 2022-03-30 2023-01-13 北京贝来生物科技有限公司 一种激活肿瘤免疫的基因修饰干细胞制备方法
EP4531916A1 (en) 2022-06-02 2025-04-09 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
CN114966061B (zh) * 2022-07-28 2022-10-21 中国食品药品检定研究院 一种抗ox40抗体的生物活性检测方法
WO2024054992A1 (en) 2022-09-09 2024-03-14 Bristol-Myers Squibb Company Methods of separating chelator
WO2024196952A1 (en) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Tumor subtype assessment for cancer therapy
CN121712571A (zh) 2023-08-15 2026-03-20 百时美施贵宝公司 陶瓷羟基磷灰石色谱流通法
US20250215087A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg depleting agent

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US6242566B1 (en) 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
AU7603800A (en) 1999-09-24 2001-04-24 Human Genome Sciences, Inc. 32 human secreted proteins
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
WO2005075514A2 (en) 2004-03-10 2005-08-18 Lonza Ltd. Method for producing antibodies
EP1685161A1 (en) 2004-08-30 2006-08-02 Lonza Biologics plc Affinity- plus ion exchange-chromatography for purifying antibodies
PT2650020T (pt) 2005-05-06 2016-12-12 Providence Health & Services - Oregon Proteína de fusão de imunoglobulina ox-40 trimérica e métodos do campo de utilização
TWI461436B (zh) * 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
BRPI0715829A2 (pt) * 2006-08-21 2013-07-23 Hoffmann La Roche terapia de tumor com um anticorpo anti-vegf
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
CA2679399A1 (en) * 2007-02-27 2008-09-04 Genetech, Inc. Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
HUE032735T2 (en) * 2007-12-14 2017-10-30 Bristol Myers Squibb Co Binding molecules for the human OX40 receptor
WO2009092014A1 (en) 2008-01-18 2009-07-23 Gagnon Peter S Enhanced purification of antibodies and antibody fragments by apatite chromatography
EP2250279B1 (en) 2008-02-08 2016-04-13 MedImmune, LLC Anti-ifnar1 antibodies with reduced fc ligand affinity
EP2398498B1 (en) * 2009-02-17 2018-09-05 UCB Biopharma SPRL Antibody molecules having specificity for human ox40
EP3252076B1 (en) 2011-01-14 2019-09-04 The Regents Of The University Of California Diagnostic use of antibodies against ror-1 protein
EP2731677B1 (en) * 2011-07-11 2018-04-18 Glenmark Pharmaceuticals S.A. Antibodies that bind to ox40 and their uses
KR101685262B1 (ko) * 2011-08-23 2016-12-21 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 항-ｏｘ４０ 항체 및 이의 사용 방법
GB201116092D0 (en) * 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
CA2863818A1 (en) * 2012-02-06 2013-08-15 Brendan CURTI Cancer treatment and monitoring methods using ox40 agonists
EP2819693A4 (en) * 2012-03-02 2015-10-28 Providence Health & Services Oregon ANTICANCER BITHERAPY BASED ON OX40 / IL-2 AGONIST
HK1220207A1 (zh) * 2013-03-12 2017-04-28 Decimmune Therapeutics Inc. 人源化抗n2抗体
NZ712903A (en) * 2013-03-18 2018-07-27 Biocerox Prod Bv Humanized anti-cd134 (ox40) antibodies and uses thereof

Also Published As

Publication number Publication date
EP3204422B1 (en) 2022-03-30
EP3204422A1 (en) 2017-08-16
RU2017115662A (ru) 2018-11-13
JP2017532037A (ja) 2017-11-02
JP2021036887A (ja) 2021-03-11
TW201619200A (zh) 2016-06-01
CL2017000885A1 (es) 2017-12-15
CO2017004516A2 (es) 2017-09-29
CN107074953A (zh) 2017-08-18
GB201517855D0 (en) 2015-11-25
US20190169303A1 (en) 2019-06-06
AU2015328090A1 (en) 2017-04-27
US20180072808A1 (en) 2018-03-15
SG11201702826XA (en) 2017-05-30
BR112017007170A2 (pt) 2017-12-19
MX2017004715A (es) 2017-06-19
AR102239A1 (es) 2017-02-15
RU2017115662A3 (enExample) 2019-05-20
JP6794348B2 (ja) 2020-12-09
GB2536324A (en) 2016-09-14
RU2709742C2 (ru) 2019-12-19
WO2016057667A1 (en) 2016-04-14
US20160137740A1 (en) 2016-05-19
IL251537A0 (en) 2017-05-29
US10150815B2 (en) 2018-12-11
EP3204422A4 (en) 2018-08-15
CA2963798A1 (en) 2016-04-14
US9738723B2 (en) 2017-08-22
ES2914177T3 (es) 2022-06-07

Similar Documents

Publication Publication Date Title
KR20170064550A (ko) 인간화 항-ox40 항체 및 이의 용도
AU2018250301B2 (en) Anti-ICOS agonist antibodies and uses thereof
RU2755503C2 (ru) Анти-lag-3 антитела и их композиции
KR102379464B1 (ko) 항-pd-l1 항체
DK2614082T3 (en) 4-1BB BINDING MOLECULES
JP2022115922A (ja) 抗ｔｉｇｉｔ抗体、抗ｐｖｒｉｇ抗体およびそれらの組み合せ
KR20240017912A (ko) 항-ccr8 항체 및 이의 용도
KR102604433B1 (ko) 항-icos 항체
JP2021508676A (ja) 抗ｔｉｇｉｔ抗体並びに治療剤及び診断剤としてのその使用
KR20200061402A (ko) 항-cd38 항체 및 항-cd3 및 항-cd28 항체와의 조합
KR20190133160A (ko) 항-gprc5d 항체 및 항-gprc5d 항체를 포함하는 분자
TW202428604A (zh) 結合至ilt4的抗體
KR20180100224A (ko) 인간 인터루킨-2에 대한 면역-자극 인간화 단일클론 항체, 및 이의 융합 단백질
TW201605901A (zh) Ｐｄ－１抗體、其抗原結合片段及其醫藥用途
KR20150117259A (ko) Tl1a에 결합하는 항체 및 이의 용도
CN106795223B (zh) 针对Fcγ受体IIB及Fcε受体的抗体
KR20180002597A (ko) 암 치료법의 효능을 증강시키기 위한 조성물 및 방법
CN109195987A (zh) 针对IL7受体胞外域的α链的非拮抗性抗体及其在癌症治疗中的应用
TW202313110A (zh) 癌症之治療
JP2019531732A (ja) 抗ｃｄ２７抗体、その抗原結合性フラグメント、およびそのものの医学的使用
JP2025511356A (ja) Ｐｄ－ｌ１及びｃｄ４０を標的とする抗原結合タンパク質及びその製造と応用
RU2812910C2 (ru) Антитела к cd38 и комбинации с антителами к cd3 и cd28
CN117460529A (zh) 抗icos抗体的用途
KR20260030924A (ko) 항-icos 항체
HK40003736B (en) Anti-icos antibodies

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170508

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201006

Comment text: Request for Examination of Application

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20210412